このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Solid Biosciences 将来の成長

Future 基準チェック /26

Solid Biosciencesの収益は年間9.4%で減少すると予測されていますが、年間収益は年間64.4%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に-80% 12.5%なると予測されています。

主要情報

-9.4%

収益成長率

12.5%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	64.9%
将来の株主資本利益率	-80.0%
アナリストカバレッジ	Good
最終更新日	27 Jun 2024

今後の成長に関する最新情報

Recent updates

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Apr 30

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Apr 28

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Mar 17

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Oct 28

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Jul 13

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Mar 17

Soild Bio sinks 13% after Sarepta data misses goal

Jan 08

Solid Biosciences launches $90M private placement

Dec 11

Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data

Nov 10

業績と収益の成長予測

NasdaqGS:SLDB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2	-148	-214	-194	5
12/31/2025	4	-118	-108	-121	7
12/31/2024	3	-100	-60	-59	8
3/31/2024	N/A	-90	-93	-91	N/A
12/31/2023	N/A	-96	-96	-94	N/A
9/30/2023	N/A	-91	-110	-108	N/A
6/30/2023	N/A	-90	-113	-110	N/A
3/31/2023	6	-91	-102	-99	N/A
12/31/2022	8	-86	-101	-98	N/A
9/30/2022	11	-89	-87	-84	N/A
6/30/2022	15	-87	-85	-82	N/A
3/31/2022	12	-81	-85	-84	N/A
12/31/2021	14	-72	-79	-78	N/A
9/30/2021	10	-75	-56	-56	N/A
6/30/2021	7	-78	-53	-53	N/A
3/31/2021	3	-78	-49	-49	N/A
12/31/2020	N/A	-88	-57	-57	N/A
9/30/2020	N/A	-99	-81	-79	N/A
6/30/2020	N/A	-107	-85	-83	N/A
3/31/2020	N/A	-114	-99	-96	N/A
12/31/2019	N/A	-117	-97	-93	N/A
9/30/2019	N/A	-107	-98	-93	N/A
6/30/2019	N/A	-97	-96	-89	N/A
3/31/2019	N/A	-89	-88	-79	N/A
12/31/2018	N/A	-75	-78	-70	N/A
9/30/2018	N/A	-67	-69	-63	N/A
6/30/2018	N/A	-62	-63	-57	N/A
3/31/2018	N/A	-55	-53	-50	N/A
12/31/2017	N/A	-39	N/A	-43	N/A
9/30/2017	N/A	-29	N/A	-35	N/A
12/31/2016	N/A	-17	N/A	-20	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SLDB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SLDB今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SLDB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SLDBの収益 ( 64.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: SLDBの収益 ( 64.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SLDB 3 年以内に赤字になると予測されています。

Solid Biosciences 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 123%

Consensus EPS estimates upgraded to US$2.79 loss

Consensus revenue estimates decrease by 50%, EPS upgraded

Consensus revenue estimates decrease by 33%, EPS upgraded

Consensus forecasts updated

Consensus forecasts updated

Recent updates

Consensus revenue estimates increase by 123%

Solid Biosciences Inc. Announces Board Resignations

Solid Biosciences Inc., Annual General Meeting, Jun 11, 2024

Buy Solid Biosciences: Unpacking Its Main Value Driver

Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Consensus EPS estimates upgraded to US$2.79 loss

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Solid Biosciences Inc. announced that it expects to receive $108.858551 million in funding from a group of investors

Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate Sgt-003

Consensus revenue estimates decrease by 50%, EPS upgraded

New minor risk - Share price stability

Solid Biosciences Inc. Appoints Gabriel Brooks as Chief Medical Officer

Consensus revenue estimates decrease by 33%, EPS upgraded

New major risk - Revenue size

New minor risk - Market cap size

Solid Biosciences Inc. Announces Executive Changes

First quarter 2023 earnings released: US$1.54 loss per share (vs US$3.37 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Solid Biosciences Inc. and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Solid Biosciences Appoints Kevin Tan as Chief Financial Officer

Solid Biosciences Inc. Announces Executive Changes

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings released: US$2.71 loss per share (vs US$2.40 loss in 3Q 2021)

Third quarter 2022 earnings released: US$2.71 loss per share (vs US$2.40 loss in 3Q 2021)

Consensus forecasts updated

Price target decreased to US$3.00

Solid Biosciences Inc. Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle

Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results

Consensus forecasts updated

Solid Biosciences Inc. (NasdaqGS:SLDB) entered into a definitive agreement to acquire AavantiBio, Inc.

Solid Biosciences to acquire gene therapy company AavantiBio

Bain Capital Engages in Discussions with Solid Biosciences

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Solid Biosciences Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq for Minimum Bid Price Requirement

Price target decreased to US$5.60

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Consensus revenue estimates fall by 12%

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Price target decreased to US$8.67

Solid Biosciences Inc. to Report Q1, 2022 Results on Apr 27, 2022

Price target decreased to US$8.67

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Price target decreased to US$7.40

Price target decreased to US$7.42

Price target decreased to US$8.50

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Solid Biosciences Inc. Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

Solid Biosciences Inc. to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

Consensus forecasts updated

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences Inc.(NasdaqGS:SLDB) dropped from Russell 2500 Growth Index

Co-Founder & Independent Director Matthew Arnold has left the company

Solid Biosciences Inc Announces Two Additional Patients Dosed in the IGNITE DMD Clinical Trial

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Solid Biosciences Reports Efficacy and Safety Data from the Ongoing Ignite Dmd Clinical Trial and Resumption of Patient Dosing in the 2E14 Vg/Kg Cohort

Solid Biosciences Inc. Announces Management Changes

New 90-day high: US$9.74

CFO & Treasurer has left the company

Co-founder exercised options and sold US$66k worth of stock

Soild Bio sinks 13% after Sarepta data misses goal

New 90-day high: US$7.79

New 90-day high: US$5.60

Solid Biosciences launches $90M private placement

Solid Biosciences Inc. Announces Management Changes

Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data

Solid Biosciences Inc. to Report Q3, 2020 Results on Nov 05, 2020

Solid Biosciences Announces Fda Lifts Clinical Hold on Ignite Dmd Clinical Trial